SPC Logo

ECALTA 100 mg powder for concentrate for solution for infusion

Last Updated on eMC 11-Sep-2014 View document  | Pfizer Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 11-Sep-2014 and displayed until Current

Reasons for adding or updating:

  • Change to section 6 - marketing authorisation holder

Updated on 04-Sep-2014 and displayed until 11-Sep-2014

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision
  • Change to information for healthcare professionals

Updated on 28-Aug-2014 and displayed until 04-Sep-2014

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision
  • Change to information for healthcare professionals

Updated on 28-Aug-2014 and displayed until 28-Aug-2014

Reasons for adding or updating:

  • Improved presentation of PIL

Updated on 27-Aug-2014 and displayed until 28-Aug-2014

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision
  • Change to information for healthcare professionals

Updated on 15-Aug-2013 and displayed until 27-Aug-2014

Reasons for adding or updating:

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 04-Sep-2012 and displayed until 15-Aug-2013

Reasons for adding or updating:

  • Change to date of revision
  • Change to side-effects

Updated on 18-Jul-2012 and displayed until 04-Sep-2012

Reasons for adding or updating:

  • Change to date of revision
  • Change to side-effects

Updated on 11-Mar-2011 and displayed until 18-Jul-2012

Reasons for adding or updating:

  • Change to storage instructions

Updated on 28-Jan-2011 and displayed until 11-Mar-2011

Reasons for adding or updating:

  • Correction of spelling/typing errors

Updated on 02-Nov-2010 and displayed until 28-Jan-2011

Reasons for adding or updating:

  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to side-effects

Updated on 07-Jan-2010 and displayed until 02-Nov-2010

Reasons for adding or updating:

  • New PIL for new product

Company contact details

Pfizer Limited

Company image
Address

Ramsgate Road, Sandwich, Kent, CT13 9NJ

Fax

+44 (0)1304 656 221

Telephone

+44 (0)1304 616 161

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

anidulafungin

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue